NovaBridge Biosciences (NBP)
NBP Stock Price Chart
Explore NovaBridge Biosciences interactive price chart. Choose custom timeframes to analyze NBP price movements and trends.
NBP Company Profile
Discover essential business fundamentals and corporate details for NovaBridge Biosciences (NBP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Jan 2020
Employees
32.00
Website
https://www.i-mabbiopharma.comCEO
Xi-Yong Fu
Description
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
NBP Financial Timeline
Browse a chronological timeline of NovaBridge Biosciences corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 19 Aug 2026
EPS estimate is -$0.14.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$0.01.
Earnings released on 7 Apr 2026
EPS came in at -$0.22 falling short of the estimated -$0.04 by -528.57%.
Earnings released on 18 Dec 2025
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%.
Earnings released on 20 Aug 2025
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%.
Earnings released on 15 May 2025
EPS came in at -$0.02 surpassing the estimated -$0.06 by +68.42%.
Earnings released on 31 Mar 2025
EPS came in at -$0.06 matching the estimated -$0.06.
Earnings released on 14 Nov 2024
EPS came in at -$0.25 falling short of the estimated -$0.16 by -56.25%.
Earnings released on 28 Aug 2024
EPS came in at -$0.07 surpassing the estimated -$0.51 by +86.27%.
Earnings released on 5 Jun 2024
EPS came in at $0.04 .
Earnings released on 29 Mar 2024
EPS came in at -$0.59 falling short of the estimated -$0.10 by -513.00%, while revenue for the quarter reached $160.35k .
Earnings released on 30 Sept 2023
EPS came in at -$0.57 , while revenue for the quarter reached $546.77k .
Earnings released on 17 Aug 2023
EPS came in at -$0.64 falling short of the estimated -$0.26 by -146.64%, while revenue for the quarter reached $1.36m , beating expectations by +41.23%.
Earnings released on 31 Mar 2023
EPS came in at -$0.68 falling short of the estimated -$0.49 by -37.89%, while revenue for the quarter reached $1.43m .
Earnings released on 30 Sept 2022
EPS came in at -$1.23 , while revenue for the quarter reached -$19.14m .
Earnings released on 30 Aug 2022
EPS came in at -$0.95 falling short of the estimated -$0.16 by -494.23%, while revenue for the quarter reached $3.87m , beating expectations by +52.74%.
Earnings released on 31 Mar 2022
EPS came in at -$1.00 , while revenue for the quarter reached $4.08m .
Earnings released on 29 Mar 2022
EPS came in at -$1.26 falling short of the estimated -$0.34 by -269.12%, while revenue for the quarter reached $5.52m , missing expectations by -54.49%.
Earnings released on 12 Nov 2021
EPS came in at -$1.24 , while revenue for the quarter reached $5.44m .
Earnings released on 31 Aug 2021
EPS came in at -$1.13 falling short of the estimated -$0.36 by -214.96%, while revenue for the quarter reached $1.37m , missing expectations by -73.58%.
NBP Stock Performance
Access detailed NBP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
